本帖最后由 老马 于 2012-1-13 21:20 编辑 : A6 m3 k1 @0 R1 q$ D
' n2 J9 ` d' W% Z
爱必妥和阿瓦斯丁的比较
; i9 x0 } S( ?2 g. r
6 @/ G7 ^- L3 y. [& P% g; Ahttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
; ` Q3 `- h( q3 V
* t* V" _% P8 D
# C) H9 _! T7 \. b. \6 Mhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/) |% v1 W4 H% j" @) H7 x: ? {
==================================================# Z ^% g- g) a" v0 Z+ O q: j! c
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
. g6 n5 e0 \3 k; L% NPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" Q& k! o% _/ L% `3 M2 UResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
8 `% H/ z/ ?3 P; ~0 C
|
显身卡
